AGIO Quote, Financials, Valuation and Earnings

Fulcrum Therapeutics, Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of 69.26%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Fulcrum Therapeutics, Inc.'s return on equity of -31.15%.

Agios Pharmaceuticals, Inc. has a consensus price target of $32.13, signalling upside risk potential of 17.16%. On the other hand Fulcrum Therapeutics, Inc. has an analysts' consensus of $14.56 which suggests that it could grow by 66.16%. Given that Fulcrum Therapeutics, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Fulcrum Therapeutics, Inc. is more attractive than Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.867, which suggesting that the stock is 13.282% less volatile than S&P 500. In comparison Fulcrum Therapeutics, Inc. has a beta of 3.172, suggesting its more volatile than the S&P 500 by 217.163%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fulcrum Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Fulcrum Therapeutics, Inc. pays out -- of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are larger than Fulcrum Therapeutics, Inc. quarterly revenues of --. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is lower than Fulcrum Therapeutics, Inc.'s net income of -$19.6M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Fulcrum Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 35.31x versus -- for Fulcrum Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of -19.69%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Moderna, Inc.'s return on equity of -30.18%.

Agios Pharmaceuticals, Inc. has a consensus price target of $32.13, signalling upside risk potential of 17.16%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Moderna, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Moderna, Inc. is more attractive than Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.867, which suggesting that the stock is 13.282% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is higher than Moderna, Inc.'s net income of -$200M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 35.31x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of 21.32%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Pfizer Inc.'s return on equity of 10.84%.

Agios Pharmaceuticals, Inc. has a consensus price target of $32.13, signalling upside risk potential of 17.16%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Agios Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Agios Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.867, which suggesting that the stock is 13.282% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 35.31x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of -40.15%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Agios Pharmaceuticals, Inc. has a consensus price target of $32.13, signalling upside risk potential of 17.16%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 125.96%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.867, which suggesting that the stock is 13.282% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is lower than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 35.31x versus 1.44x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.